EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Ketamine in super‐refractory status epilepticus: Combined value of inflammatory biomarkers and EEG features

Stefania Pavan iD, Giulia Mazzon iD, Giovanni Furlanis iD, David Stokelj, Matteo Cegalin, Jacopo Della Toffola iD, Claudia Castellabate, Valeria Cecchinato, Erik Roman-Pognuz iD, Marinella Tomaselli iD, Paolo Manganotti iD

Epilepsia · 2026-07 · 67 (7) · 3457-3470

DOI: 10.1002/epi.70242 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Epilepsia, online erschienen am 13.04.2026. Verfasst von Stefania Pavan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, Trieste University Hospital-ASUGI, University of Trieste, Trieste, I…. Hauptthemen laut MEDLINE: Ketamine, Status Epilepticus, Electroencephalography, Drug Resistant Epilepsy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to evaluate the efficacy and safety of intravenous ketamine in a cohort of patients with super‐refractory status epilepticus (SRSE) and to explore whether specific clinical, laboratory, and EEG patterns could predict treatment response.

Methods

This single‐center retrospective observational study included all adult patients treated with intravenous ketamine for SRSE between August 2020 and September 2025, at the University Hospital of Trieste. Demographic, clinical, laboratory, and EEG data were collected from medical records. EEG recordings obtained during and after ketamine infusion were analyzed according to American Clinical Neurophysiology Society (ACNS) terminology. Associations between baseline characteristics, clinical outcomes, and laboratory and EEG patterns were examined using univariate statistics, and an exploratory EEG severity score, the KEOS (Ketamine EEG Outcome Score), was constructed to assess predictive accuracy.

Results

Twelve patients met the inclusion criteria. The sustained response rate, defined as seizure cessation without recurrence after complete anesthetic withdrawal, was 58%. Non‐responders exhibited a profound hyperinflammatory state at the onset of status epilepticus, with significantly higher levels of composite indices such as the neutrophil‐to‐lymphocyte ratio (NLR), Systemic Inflammation Response Index (SIRI), and Systemic Immune‐Inflammation Index (SII). Moreover, a “beta background” pattern was significantly more frequent among responders, whereas discontinuous or burst‐suppression backgrounds were associated with poor outcomes. The KEOS demonstrated excellent discrimination (area under the curve [AUC] = .97, sensitivity = 100%, specificity = 85.7%). Adverse events were mild, with transient liver enzyme elevation in 42% of patients. Significance Intravenous ketamine showed moderate efficacy and a favorable safety profile in this SRSE cohort. The identification of specific EEG signatures together with systemic inflammatory biomarkers suggests the potential for a more biologically informed approach to ketamine monitoring and treatment optimization. However, given the limited sample size, these findings should be interpreted as hypothesis‐generating and warrant validation in larger, prospective multicenter studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetamineStatus EpilepticusElectroencephalographyDrug Resistant EpilepsyHumansFemaleMaleRetrospective StudiesBiomarkersAdultMiddle AgedInflammationTreatment Outcome

Stichwörter der Autor:innen

EEG monitoringNMDA receptor antagonistinflammatory biomarkersneurocritical carestatus epilepticus

Substanzen

KetamineBiomarkers

Autor:innen und Institutionen

  • Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, Trieste University Hospital-ASUGI, University of Trieste, Trieste, Italy.
  • Clinical Neurophysiology Unit, Department of Medicine, Surgery and Health Sciences, Trieste University Hospital-ASUGI, University of Trieste, Trieste, Italy.
  • Intensive Care Unit, Department of Anesthesia and Intensive Care, Department of Medical Science, Trieste University Hospital-ASUGI, University of Trieste, Trieste, Italy.

ORCID-Profile: Stefania Pavan, Giulia Mazzon, Giovanni Furlanis, Jacopo Della Toffola, Erik Roman-Pognuz, Marinella Tomaselli, Paolo Manganotti

Zitieren

APA

Pavan, S., Mazzon, G., Furlanis, G., Stokelj, D., Cegalin, M., Della Toffola, J., Castellabate, C., Cecchinato, V., Roman-Pognuz, E., Tomaselli, M., & Manganotti, P. (2026). Ketamine in super‐refractory status epilepticus: Combined value of inflammatory biomarkers and EEG features. Epilepsia, 67(7), 3457-3470. https://doi.org/10.1002/epi.70242

Vancouver

Pavan S, Mazzon G, Furlanis G, Stokelj D, Cegalin M, Della Toffola J, et al. Ketamine in super‐refractory status epilepticus: Combined value of inflammatory biomarkers and EEG features. Epilepsia. 2026;67(7):3457-3470. doi:10.1002/epi.70242

BibTeX
@article{Pavan2026,
  author = {Pavan, Stefania and Mazzon, Giulia and Furlanis, Giovanni and Stokelj, David and Cegalin, Matteo and Della Toffola, Jacopo and Castellabate, Claudia and Cecchinato, Valeria and Roman-Pognuz, Erik and Tomaselli, Marinella and Manganotti, Paolo},
  title = {Ketamine in super‐refractory status epilepticus: Combined value of inflammatory biomarkers and EEG features},
  journal = {Epilepsia},
  year = {2026},
  volume = {67},
  number = {7},
  pages = {3457--3470},
  doi = {10.1002/epi.70242}
}
Kostenlos starten →